Literature DB >> 11092527

Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR.

A Yuan1, C J Yu, K T Luh, W J Chen, F Y Lin, S H Kuo, P C Yang.   

Abstract

A reliable quantitative method for measuring gene product expression is important in investigating the relationship between growth factors and tumor biological behavior. In this study, we quantified the expression of vascular endothelial growth factor (VEGF) mRNA in 104 paired samples of lung cancer tissue and the surrounding nontumorous lung tissue using a new kinetic quantitative polymerase chain reaction (PCR) method, ie, real-time quantitative reverse transcription-PCR (RTQ RT-PCR). The samples consisted of 46 squamous cell carcinomas, 50 adenocarcinomas, and 8 undifferentiated cell carcinomas. In 17 cases, the results obtained were compared with those obtained using quantitative competitive RT-PCR (QC RT-PCR). Using RTQ RT-PCR, VEGF mRNA expression was detected and quantified in all 104 (100%) lung cancer samples and their normal counterparts. VEGF mRNA expression in the lung cancer tissue was significantly higher than in the normal counterparts (95% CI: 0.575 approximately 1.727, p < 0.001; paired t test). In 68 (65.4%) cases, VEGF mRNA expression was higher in the cancer tissue than normal tissue. VEGF mRNA expression was higher in nonsquamous cell carcinoma (p = 0.02), and higher in tumor with hilar or mediastinal lymph node metastasis (p = 0.024). QC RT-PCR was able to detect and quantify VEGF mRNA expression in 15/17 (88%) lung cancer samples and 12/17 (70.6%) normal tissue samples. The values for VEGF mRNA expression were higher in the tumor in 13 (76%) cases. Comparison of the values of the VEGF mRNA expression quantified using RTQ RT-PCR or QC RT-PCR showed a good correlation between results obtained using these two methods, both in cancer tissue (r = 0.68, p = 0.0025) and normal counterpart (r = 0.53, p = 0.027). Agreement between the results for the relative expression of VEGF mRNA expression in cancer and normal tissue obtained using these two methods was seen in 14/16 cases (88%). We conclude that RTQ RT-PCR is as accurate as QC RT-PCR and is more sensitive than QC RT-PCR in detecting and quantifying VEGF mRNA expression in lung cancer and normal tissues, and both methods reveal that the VEGF mRNA expression is higher in lung cancer tissue than in healthy lung tissue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092527     DOI: 10.1038/labinvest.3780177

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms.

Authors:  Stacey D Finley; Aleksander S Popel
Journal:  AAPS J       Date:  2012-05-01       Impact factor: 4.009

2.  Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

Authors:  Elana S Tykocinski; Ryan A Grant; Gurpreet S Kapoor; Jaroslaw Krejza; Leif-Erik Bohman; Timothy A Gocke; Sanjeev Chawla; Casey H Halpern; Joanna Lopinto; Elias R Melhem; Donald M O'Rourke
Journal:  Neuro Oncol       Date:  2012-04-04       Impact factor: 12.300

3.  Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.

Authors:  Gurpreet S Kapoor; Timothy A Gocke; Sanjeev Chawla; Robert G Whitmore; Ali Nabavizadeh; Jaroslaw Krejza; Joanna Lopinto; Justin Plaum; Eileen Maloney-Wilensky; Harish Poptani; Elias R Melhem; Kevin D Judy; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

4.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Authors:  Stacey D Finley; Aleksander S Popel
Journal:  J Natl Cancer Inst       Date:  2013-05-13       Impact factor: 13.506

5.  Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.

Authors:  Stacey D Finley; Marianne O Engel-Stefanini; P I Imoukhuede; Aleksander S Popel
Journal:  BMC Syst Biol       Date:  2011-11-21

6.  Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.

Authors:  Stacey D Finley; Manjima Dhar; Aleksander S Popel
Journal:  Front Oncol       Date:  2013-07-30       Impact factor: 6.244

7.  The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology.

Authors:  Soyeon Lee; Hyo Gyoung Kang; Jin Eun Choi; Jang Hyuck Lee; Hyo Jung Kang; Sun Ah Baek; Eungbae Lee; Yangki Seok; Won Kee Lee; Shin Yup Lee; Seung Soo Yoo; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; Sukki Cho; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2016-11       Impact factor: 2.153

8.  The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer.

Authors:  Y Ohta; Z Nozaki; H Nozawa; T Kamesui; Y Tsunezuka; M Oda; G Watanabe
Journal:  Jpn J Cancer Res       Date:  2001-03

9.  Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.

Authors:  Ahmed Abdallah; Mohamed Belal; Ahmed El Bastawisy; Rabab Gaafar
Journal:  Oncol Lett       Date:  2014-03-31       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.